Reductase-mediated metabolism of motexafin gadolinium (Xcytrin®) in rat and human liver subcellular fractions and purified enzyme preparations

Journal of Pharmaceutical Sciences

Volumn 94, Issue 3, 2005, Pages 559-570

  Mani, Chitra ^a   Upadhyay, Shubhra ^a   Lacy, Steve ^a   Boswell, Carry W ^a   Miles, Dale R ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

Cancer; DT diaphorase; HPLC (high performance liquid chromatography); Mass spectrometry; Metabolism; Motexafin gadolinium; NAD(P)H oxidoreductase; Reductases; Texaphyrin; Xcytrin, microsomes

Indexed keywords

CARBON MONOXIDE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; DICOUMAROL; DRUG METABOLITE; GADOLINIUM TEXAPHYRIN; KETOCONAZOLE; OXIDOREDUCTASE; PCI 0108; PHENOBARBITAL; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANAEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME PURIFICATION; HUMAN; HUMAN TISSUE; LIVER; LIVER CYTOSOL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RABBIT; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 16444383795     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20274     Document Type: Article

References (26)

1. Mody TD, Fu L, Sessler JL. 2001. Texaphyrins: Synthesis and development of a novel class of therapeutic agents. In: Karlin KD, editor. Progress in inorganic chemistry. New York: John Wiley & Sons Inc., pp 551-598.
2. Young SW, Qing F, Harriman A, Sessler JL, Dow WC, Mody TD, Hemmi GW, Hao Y, Miller RA. 1996. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI [published correction appears in Proc Natl Acad Sci USA 1999;96:2569], Proc Natl Acad Sci USA 93:6610-6615.
3. Young SW, Qing F, Harriman A, Sessler JL, Dow WC, Mody TD, Hemmi GW, Hao Y, Miller RA. 1996. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI [published correction appears in Proc Natl Acad Sci USA 1999;96:2569], Proc Natl Acad Sci USA 93:6610-6615.
4. Sessler JL, Tvermoes NA, Guldi DM, Mody TD, Allen WE. 1999. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem A 103:787-794.
5. Magda D, Lepp C, Gerasimchuk N, Lee I, Sessler JL, Lin A, Biaglow JE, Miller RA. 2001. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51:1025-1036.
6. Magda D, Gerasimchuk N, Lecane P, Miller RA, Biaglow JE, Sessler JL. 2002. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun 2730-2731.
7. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF. 2002. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3453.
8. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler R, Miles D, Miller RA, Renschler MF. 2001. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074-2083.
9. Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL, Miller R, Engel J, Young S, Miles D, Renschler MF. 1999. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5:739-745.
10. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA. 1999. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45:981-989.
11. Upadhyay S, Shemirani A, Miles D, Lacy S. 2000. Metabolism of Xcytrin (motexafin gadolinium, GD-tex) injection in the rat. 91st Annual Meeting of the American Association for Cancer Research. Abstract no. 5286, Vol. 41, p 833.
12. Nordlie RC, Arion WJ. 1966. Enzymatic assay of Glucose-6-phosphate. Methods Enzymol 9:619-625.
13. Taussky HH, Shorr E. 1953. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem 202:675-685.
14. Pederson TC, Aust SD. 1970. Aminopyrine demethylase. Kinetic evidence for multiple microsomal activities. Biochem Pharmacol 19:2221-2230.
15. Werringloer J. 1978. Assay of formaldehyde generated during microsomal oxidation reactions. Methods Enzymol 52:297-302.
16. Garle MJ, Fry JR. 1989. Detection of reactive metabolites in vitro. Toxicology 54:101-110.
17. Backes WL. 1993. Cytochrome P450. In: Schenkman JB, Grimes H, editors. Handbook of experimental pharmacology. Berlin: Springer-Verlag, pp 15-34.
18. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. 1985. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34:3337-3345.
19. Burke MD, Mayer RT. 1974. Ethoxyresorufin: Direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 2:583-588.
20. Nims RW, Prough RA, Lubet RA. 1984. Cytosol-mediated reduction of resorufin: A method for measuring quinone oxidoreductase. Arch Biochem Biophys 229:459-465.
21. Goeptar AR, Scheerens H, Vermeulen NP. 1995. Oxygen and xenobiotic reductase activities of cytochrome P450. Grit Rev Toxicol 25:25-65.
22. Gonzales FJ. 1992. Human cytochrome P450 problems and prospects. Trends Pharmacol Sci 13:346.
23. Murray M, Reidy GF. 1990. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42:85-101.
24. Kitamura S, Shimizu Y, Shiraga Y, Yoshida M, Sugihara K, Ohta S. 2002. Reductive metabolism of p,p′-DDT and o,p′-DDT by rat liver cytochrome P450. Drug Metab Dispos 30:113-118.
25. Ross D, Beall HD, Siegel D, Traver RD, Gustafson DL. 1996. Enzymology of bioreductive drug activation. Br J Cancer Suppl 27:S1-S8.
26. Horie S. 1991. Advances in research on DT-diaphorase-catalytic properties, regulation of activity and significance in the detoxification of foreign compounds. Kitasato Arch Exp Med 63:11-30.